Faissner, Simon http://orcid.org/0000-0002-3412-762X
Gold, Ralf
Funding for this research was provided by:
Ruhr-Universität Bochum
Article History
Accepted: 6 July 2022
First Online: 22 July 2022
Declarations
:
: No funding was received for the preparation of this article. Open Access funding enabled and organized by Projekt DEAL.
: Simon Faissner and Ralf Gold have no conflicts of interest that are directly relevant to the content of this article. Simon Faissner has received speaker’s and/or scientific board honoraria from Biogen, BMS, Celgene, Genesis Pharma, Novartis, and Roche and grant support from Ruhr-University Bochum, DMSG, Stiftung für therapeutische Forschung, Lead Discovery Center GmbH, and Novartis. Ralf Gold serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd., Biogen, Bayer Schering Pharma, and Novartis; has received speaker honoraria from Biogen, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, and Novartis; serves as an editor for <i>Therapeutic Advances in Neurological Diseases</i> and on the editorial boards of <i>Experimental Neurology</i> and the <i>Journal of Neuroimmunology</i>; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: SF and RG discussed data and performed the literature review. SF wrote the first draft of the manuscript. RG critically revised the manuscript. All authors read and approved the final manuscript.